Bangalore and North Carolina facilities look to expand staff after the award of two large FSPs
Quanticate, a leading global data-focused clinical research organization (CRO) today announced the expansion of its global resources to support clinical trials. The region most affected is Bangalore and North Carolina, particularly in the areas of biostatistics and statistical programming, following the award of large functional service provision (FSP) contracts with two industry-leading pharmaceutical companies.
Quanticate is looking to significantly grow its resource capabilities and will be recruiting staff over a range of roles in biostatistics and statistical programming across all levels of seniority throughout 2014 based upon its overall pipeline of work. Opportunities will include graduate to principal roles in India and the US as well as other global locations.
"The expansion of our current customers coupled with the addition of new partnerships and two large-scale FSPs, has resulted in the need to expand our resource base across all our locations,” explained Daniel Chapple, Chief Commercial Officer. “This expansion will also enable us to extend our presence to other cities in India and we are currently in the process of identifying facilities,” continued Chapple.
The addition of two new partnerships means that Quanticate is now supporting biostatistics and programming for six of the Top 8 pharmaceutical companies and has gained extensive experience in successfully supporting companies in strategic partnerships within the data field. “Many companies are seeing the benefits from companies that can offer global expertise in their niche fields rather than using full service CROs whose primary focus is monitoring and project management,” explains David Underwood, CEO of Quanticate. Underwood continues, “This approach can also drastically reduce operational oversight on the client side where successful partnerships are built on quality, performance, trust and understanding. It also means clients gain from the big benefit of having subject experts supporting their programs of work.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.